Optimizing Cholesterol Treatment in Patients With Muscle Complaints

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:70

Review

Rosenson, Robert S.¹  Baker, Steven²  Banach, Maciej^3,4  Borow, Kenneth M.⁵  Braun, Lynne T.⁶  Bruckert, Eric⁷  Brunham, Liam R.⁸  Catapano, Alberico L.^9,10,11  Mancini, G. B. John¹²  Moriarty, Patrick M.¹³  Morris, Pamela B.¹⁴  Muntner, Paul¹⁵  Ray, Kausik K.¹⁶  Stroes, Erik S.¹⁷  Taylor, Beth A.^18,19  Taylor, Valerie H.²⁰  Watts, Gerald F.^21,22  Thompson, Paul D.¹⁹ 

[1] Icahn Sch Med Mt Sinai, Mt Sinai Heart, Dept Med, New York, NY 10029 USA

[2] McMaster Univ, Neuromuscular Dis Clin, Dept Med, Hamilton, ON, Canada

[3] Med Univ Lodz, Dept Hypertens, Lodz, Poland

[4] Univ Zielona Gora, Cardiovasc Res Ctr, Zielona Gora, Poland

[5] MediMergent, Natl Medicat Safety Outcomes & Adherence Program, Rockville, MD USA

[6] Rush Univ, Coll Nursing, Med Ctr, Dept Adult Hlth & Gerentol Nursing, Chicago, IL 60612 USA

[7] Hop La Pitie Salpetriere, Endocrinol Dept, Inst Cardiometab & Nutr ICAN, Paris, France

[8] Univ Vancouver, Dept Med, Vancouver, BC, Canada

[9] Univ Milan, Dept Pharmacol & Biomol Sci, IRCCS Multimed, Milan, Italy

[10] Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN USA

[11] Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN USA

[12] Univ British Columbia, Div Cardiol, Dept Med, Vancouver, BC, Canada

[13] Univ Kansas, Med Ctr, Div Internal Med, Div Clin Pharmacol, Kansas City, KS 66103 USA

[14] Med Univ South Carolina, Div Cardiol, Dept Med, Charleston, SC USA

[15] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA

[16] Imperial Coll London, Dept Primary Care & Publ Hlth, Imperial Ctr Cardiovasc Dis Prevent, London, England

[17] AMC, Dept Vasc Med, Amsterdam, Netherlands

[18] Univ Connecticut, Dept Kinesiol, Storrs, CT USA

[19] Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA

[20] Univ Toronto, Womens Coll Hosp, Dept Psychiat, Toronto, ON, Canada

[21] Royal Perth Hosp, Dept Cardiol, Cardiometab Serv, Perth, WA, Australia

[22] Univ Western Australia, Sch Med, Perth, WA, Australia

关键词: cardiovascular disease;    low-density lipoprotein;    myalgia;    myopathy;    statin intolerance;   

DOI  :  10.1016/j.jacc.2017.07.752

来源: Elsevier

【 摘 要 】

Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms. (J Am Coll Cardiol 2017;70:1290-301) (C) 2017 by the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

【 授权许可】

Free